• Publications
  • Influence
Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients.
Fibroblast growth factor 23 (FGF23) exerts its effect by binding to its cognate FGF receptor 1 (FGFR1) in the presence of its co-receptor Klotho. Parathyroid glands express both FGFR1 and Klotho, andExpand
  • 219
  • 9
Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.
  • 193
  • 8
FGF23-parathyroid interaction: implications in chronic kidney disease.
Over the past few years there have been considerable advances in our understanding of the physiological regulation of mineral homeostasis. One of the most important breakthroughs is theExpand
  • 113
  • 4
Diseases of the parathyroid gland in chronic kidney disease
During the past few years, remarkable advances have been made in the understanding and the management of parathyroid diseases in patients with chronic kidney disease (CKD). One of the importantExpand
  • 42
  • 4
Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan.
Many postmenopausal women have osteopenia, a condition characterized by loss of bone mineral density (BMD) that is not as severe as in osteoporosis. The objective of this study was to estimate theExpand
  • 22
  • 4
PTH/PTHrP Receptor Mediates Cachexia in Models of Kidney Failure and Cancer.
Cachexia is a wasting syndrome associated with elevated basal energy expenditure and loss of adipose and muscle tissues. It accompanies many chronic diseases including renal failure and cancer and isExpand
  • 109
  • 3
Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism.
Parathyroidectomy (PTx) drastically improves biochemical parameters and clinical symptoms related to severe secondary hyperparathyroidism (SHPT) but the effect of PTx on survival has not beenExpand
  • 106
  • 3
Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan.
BACKGROUND Cinacalcet effectively reduces elevated levels of parathyroid hormone (PTH) in patients with secondary hyperparathyroidism (SHPT), even those with severe disease for whom parathyroidectomyExpand
  • 33
  • 3
Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder
Chronic kidney disease-mineral and bone disorder (CKD-MBD) is an important risk factor in patients with CKD, and some medications for treating CKD-MBD have been recently marketed. Because assessmentExpand
  • 10
  • 3
Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Disturbances in mineral and bone metabolism play a critical role in the pathogenesis of cardiovascular complications in patients with chronic kidney disease (CKD). The term "renal osteodystrophy" hasExpand
  • 135
  • 2